Eli Lilly shares slump after earnings report

Eli Lilly (LLY.US) shares fell over 5.5 % after the company posted weaker than expected quarterly figures. Drugmaker earned $1.54 per share while analysts' expected earnings of $1.71 per share.  Revenue rose 5% to $5.741 billion from $5.477 billion in the previous quarter, but also came in below estimates of $5.875 billion due to the poor sales of its diabetes drugs. Also CEO David Ricks also pointed out to CNBC that investments in Covid-19 treatments that were not in its prior guidance also hurt results.

Separately, an independent committee  recommended the end of clinical trials of Eli Lilly’s Covid-19 antibody drug bamlanivimab in combination with Gilead Sciences (GILD.US ) antiviral treatment remdesivir as it did not show a benefit.

Eli Lilly (LLY.US) stock tumbled to a nearly seven-month low during today's session. Currently price is testing local support at $133.00. If the current sentiment prevails, the downward move could be extended to the $122.40 handle. However, should bulls regain control, then resistance at $140.00 could be at risk. Source: xStation5

This content has been created by XTB S.A. This service is provided by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, entered in the register of entrepreneurs of the National Court Register (Krajowy Rejestr Sądowy) conducted by District Court for the Capital City of Warsaw, XII Commercial Division of the National Court Register under KRS number 0000217580, REGON number 015803782 and Tax Identification Number (NIP) 527-24-43-955, with the fully paid up share capital in the amount of PLN 5.869.181,75. XTB S.A. conducts brokerage activities on the basis of the license granted by Polish Securities and Exchange Commission on 8th November 2005 No. DDM-M-4021-57-1/2005 and is supervised by Polish Supervision Authority.